Hikma reported a disappointing set of H1 17 results, with both top-line and profitability coming below the Street’s expectations. H1 17 revenue increased 1% to $895m (5% in cc, including two months of contribution from the acquisition of Roxane/ West-Ward Columbus – acquisition completed on 29 February 2016) with all three segments underperforming (particularly the Branded and Injectables segments). While the Branded segment was undermined by the challenging market situation in th
29 Sep 2017
Challenging H1; tougher times ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Challenging H1; tougher times ahead
Hikma Pharmaceuticals Plc (HIK:LON) | 1,806 180.6 0.6% | Mkt Cap: 4,007m
- Published:
29 Sep 2017 -
Author:
Jyoti Prakash -
Pages:
4
Hikma reported a disappointing set of H1 17 results, with both top-line and profitability coming below the Street’s expectations. H1 17 revenue increased 1% to $895m (5% in cc, including two months of contribution from the acquisition of Roxane/ West-Ward Columbus – acquisition completed on 29 February 2016) with all three segments underperforming (particularly the Branded and Injectables segments). While the Branded segment was undermined by the challenging market situation in th